TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky lifted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 71.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 76,115 shares of the biopharmaceutical company's stock after buying an additional 31,665 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in TG Therapeutics were worth $3,001,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. NBC Securities Inc. increased its holdings in TG Therapeutics by 82,300.0% during the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 823 shares during the period. Golden State Wealth Management LLC increased its holdings in TG Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 433 shares during the period. Vermillion Wealth Management Inc. purchased a new position in TG Therapeutics during the 4th quarter worth $30,000. USA Financial Formulas purchased a new position in TG Therapeutics during the 1st quarter worth $57,000. Finally, Quadrant Capital Group LLC increased its holdings in TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after purchasing an additional 975 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Up 1.0%

NASDAQ TGTX traded up $0.37 during midday trading on Friday, hitting $36.90. 1,532,200 shares of the company traded hands, compared to its average volume of 1,462,069. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.02 and a quick ratio of 3.04. The company has a market cap of $5.86 billion, a PE ratio of 153.75 and a beta of 1.91. The company's 50-day simple moving average is $36.73 and its 200-day simple moving average is $35.83. TG Therapeutics, Inc. has a 52 week low of $16.65 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). The company had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The firm's revenue was up 90.4% compared to the same quarter last year. During the same period last year, the business posted ($0.07) EPS. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a report on Thursday, July 10th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, TG Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $43.80.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the sale, the director owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This trade represents a 4.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.64% of the company's stock.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.